Stock Events

Stock Events

Werewolf Therapeutics 

$0.3531
43
-$0.15-29.44% Friday 20:00
-$0.00-0.88%Friday 23:52After hours

Statistics

Day High
0.359
Day Low
0.353
52W High
2.38
52W Low
0.27
Volume
28,726
Avg. Volume
-
Mkt Cap
17.16M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

5NovExpected
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q1 2026
Q2 2026
Next
-0.47
-0.29
-0.1
0.08
Expected EPS
-0.22
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
0Revenue
-60.82MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow HOWL. It's not an investment recommendation.
NVIDIA
6
NVDA
Tesla
5
TSLA
Apple
4
AAPL
Realty Income
4
O

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bristol-Myers Squibb
BMY
Mkt Cap117.58B
Bristol Myers Squibb is a leading biopharmaceutical company that competes in the oncology space, directly challenging Werewolf Therapeutics' cancer immunotherapy approaches.
Merck
MRK
Mkt Cap305.12B
Merck & Co., Inc. is a global healthcare company that develops immunotherapy treatments for cancer, competing with Werewolf Therapeutics' innovative therapies.
Gilead Sciences
GILD
Mkt Cap161.19B
Gilead Sciences, Inc. focuses on the development of drugs for cancer treatment, making it a competitor in the oncology market alongside Werewolf Therapeutics.
AMGEN
AMGN
Mkt Cap196.12B
Amgen Inc. is a biotechnology company engaged in the discovery of novel cancer treatments, competing with Werewolf Therapeutics in the biopharmaceutical sector.
Regeneron Pharmaceuticals
REGN
Mkt Cap69.67B
Regeneron Pharmaceuticals, Inc. is involved in the development of cancer immunotherapies, directly competing with Werewolf Therapeutics' focus on modulating the immune system to fight cancer.
Novartis
NVS
Mkt Cap293.94B
Novartis AG is a healthcare company that offers a range of cancer treatments, including immunotherapies that compete with Werewolf Therapeutics' product pipeline.
Pfizer
PFE
Mkt Cap137.76B
Pfizer Inc. is a global pharmaceutical corporation with a strong presence in the oncology market, making it a competitor to Werewolf Therapeutics.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a major player in the development of cancer treatments, including immunotherapies that rival Werewolf Therapeutics' approaches.
Astrazeneca
AZN
Mkt Cap266.15B
AstraZeneca PLC is a biopharmaceutical company focusing on the development of cancer therapies, competing with Werewolf Therapeutics in the oncology sector.
Johnson & Johnson
JNJ
Mkt Cap618.61B
Johnson & Johnson is a diversified healthcare company that develops and markets cancer treatments, competing with Werewolf Therapeutics in the pharmaceutical and biotechnology industry.

About

Werewolf Therapeutics, Inc. is a biopharmaceutical firm dedicated to developing novel therapies that activate the body's immune system to combat cancer. Leveraging its exclusive PREDATOR platform, the company crafts conditionally activated molecules designed to stimulate both adaptive and innate immunity. This strategic approach aims to circumvent the shortcomings often associated with traditional proinflammatory immune treatments. Key among its product pipeline are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule targeting advanced solid tumors, and WTX-330, an Interleukin-12 INDUKINE molecule also designed for conditional activation, intended for advanced or metastatic solid tumors or lymphomas that have relapsed or are refractory. Furthermore, Werewolf Therapeutics is progressing WTX-613, a conditionally activated interferon alpha INDUKINE molecule, for addressing solid tumors and hematologic malignancies. The company was founded in 2017 and operates from its headquarters in Cambridge, Massachusetts.
Show more...
CEO
Dr. Daniel J. Hicklin Ph.D.
Employees
14
Country
United States
ISIN
US95075A1079

Listings

XNAS
US
HOWL
BOATS
BOATS
HOWL.BOATS

0 Comments

Share your thoughts

FAQ

What is Werewolf Therapeutics stock price today?▼
The current price of HOWL is $0.35 USD — it has decreased by -29.44% in the past 24 hours. Watch Werewolf Therapeutics stock price performance more closely on the chart.
What is Werewolf Therapeutics stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XNAS exchange Werewolf Therapeutics stocks are traded under the ticker HOWL.
Is Werewolf Therapeutics stock price growing?▼
HOWL stock has fallen by -17.31% compared to the previous week, the month change is a +3.73% rise, over the last year Werewolf Therapeutics has showed a -69.56% decrease.
What is Werewolf Therapeutics market cap?▼
Today Werewolf Therapeutics has the market capitalization of 17.16M
When is the next Werewolf Therapeutics earnings date?▼
Werewolf Therapeutics is going to release the next earnings report on November 05, 2026.
What were Werewolf Therapeutics earnings last quarter?▼
HOWL earnings for the last quarter are 0.08 USD per share, whereas the estimation was -0.28 USD resulting in a +128.57% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Werewolf Therapeutics revenue for the last year?▼
Werewolf Therapeutics revenue for the last year amounts to 0 USD.
What is Werewolf Therapeutics net income for the last year?▼
HOWL net income for the last year is -60.82M USD.
How many employees does Werewolf Therapeutics have?▼
As of August 02, 2026, the company has 14 employees.
In which sector is Werewolf Therapeutics located?▼
Werewolf Therapeutics operates in the Health & Wellness sector.
When did Werewolf Therapeutics complete a stock split?▼
Werewolf Therapeutics has not had any recent stock splits.
Where is Werewolf Therapeutics headquartered?▼
Werewolf Therapeutics is headquartered in Watertown, United States.